Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2012
11/29/2012US20120301407 Method of treating a mammalian teat and related compositions
11/29/2012US20120301405 Simple Mechanical Procedure and Product for Deterring Substance Abuse.
11/29/2012US20120301404 Treatment of cachexia
11/29/2012US20120301403 Polyethylene glycolated superoxide dismutase mimetics
11/29/2012US20120301402 Rap1a as a marker for cardiac arrhythmia
11/29/2012DE69314239C5 Verfahren zur Stereoselektivglycosylierung Method for Stereoselektivglycosylierung
11/29/2012DE102011103394A1 Nanomolecular transport system useful for molecular oxygen and for preparing a drug for improving the transport of oxygen in blood and oxygen-carrying blood substitute, comprises a perfluoro compound in water-soluble colloid system
11/29/2012DE102011103347A1 Nasale pharmazeutische Formulierung Nasal pharmaceutical formulation
11/29/2012DE102011103270A1 Pulverförmige Mischung zur Herstellung von Levetiracetam-haltigen Tabletten Powdered mixture for the preparation of Levetiracetam tablets containing
11/29/2012DE102006007309B4 Verbessertes Verfahren zur Herstellung von Temozolomid An improved process for the preparation of Temozolomide
11/29/2012CA2840336A1 Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
11/29/2012CA2839797A1 Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition
11/29/2012CA2837312A1 Metabotropic glutamate receptor 5 modulators and methods of use thereof
11/29/2012CA2837300A1 Fatty acid amide hydrolase inhibitors for treating pain
11/29/2012CA2837199A1 Inhibitors of lrrk2 kinase activity
11/29/2012CA2837088A1 Biphenyl derivatives useful as glucagon receptor antagonists
11/29/2012CA2837079A1 Picolinamido-propanoic acid derivatives useful as glucagon receptor antagonists
11/29/2012CA2837048A1 Expandable devices coated with a paclitaxel composition
11/29/2012CA2837045A1 Expandable devices coated with a rapamycin composition
11/29/2012CA2837027A1 4-aryl-n-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group
11/29/2012CA2836865A1 Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
11/29/2012CA2836831A1 Pharmaceutical composition
11/29/2012CA2836799A1 Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
11/29/2012CA2836791A1 Identification of compounds that disperse tdp-43 inclusions
11/29/2012CA2836666A1 Novel compounds as diacylglycerol acyltransferase inhibitors
11/29/2012CA2836612A1 Antagonists of cb1 receptor
11/29/2012CA2836480A1 Methods of treating multiple sclerosis and preserving and/or increasing myelin content
11/29/2012CA2836364A1 Erk inhibitors for use in treating spinal muscular atrophy
11/29/2012CA2836240A1 Novel imidazole derivatives useful for the treatment of arthritis
11/29/2012CA2836131A1 Synergistic combinations of polyene fungicides and non-ribosomal peptides and related methods of use
11/29/2012CA2835912A1 Pharmaceutical composition comprising fexofenadine
11/29/2012CA2835755A1 Family of aryl, heteroaryl, o-aryl and o-heteroaryl carbasugars
11/29/2012CA2835691A1 Shark-like chondroitin sulphate and process for the preparation thereof
11/29/2012CA2835528A1 Novel strain of microalga that produces squalene
11/29/2012CA2835364A1 Pharmaceutical composition of rosuvastatin calcium
11/29/2012CA2835147A1 Compositions and methods for efficacious and safe delivery of sirna using specific chitosan-based nanocomplexes
11/29/2012CA2834862A1 Pharmaceutical composition for administration to nails
11/29/2012CA2834855A1 Topical pharmaceutical composition based on semifluorinated alkanes
11/29/2012CA2833203A1 Pyridin-2 (1h) -one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
11/29/2012CA2833192A1 2-amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as vegf receptor kinase inhibitors
11/29/2012CA2833099A1 Cannabinoids for use in the treatment of neuropathic pain
11/29/2012CA2832605A1 Pyridine-and pyrazine derivatives
11/29/2012CA2831966A1 Thiazole derivatives
11/29/2012CA2828561A1 Activation of human t-helper/inducer cell, t-cytotoxic/suppressor cell, b-cell, and natural killer (nk)-cells and induction of natural killer cell activity against k562 chronic myeloid leukemia cells with modified citrus pectin
11/29/2012CA2827708A1 Solid forms of a pharmaceutically active substance
11/29/2012CA2827648A1 Tricyclic inhibitors of kinases
11/28/2012EP2527501A1 Polymorphisms predictive of anthracycline-induced cardiotoxicity
11/28/2012EP2527445A2 Treatment and prevention of influenza
11/28/2012EP2527444A2 Antisense oligonucleotide modulation of stat3 expression
11/28/2012EP2527442A2 Compounds and methods for modulating gene expression
11/28/2012EP2527441A2 Compositions and methods for treating tumors, fibrosis, and pulmonary alveolar proteinosis
11/28/2012EP2527440A1 Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
11/28/2012EP2527355A2 Polymorphic and amorphous salt forms of squalamine dilactate
11/28/2012EP2527354A1 Compositions and methods for inhibiting expression of Eg5 gene
11/28/2012EP2527353A2 Caprazol derivatives
11/28/2012EP2527352A2 Caprazene derivatives
11/28/2012EP2527351A1 Lipophosphonoxins, method of their preparation and use
11/28/2012EP2527345A1 Therapeutic pyrazolyl thienopyridines
11/28/2012EP2527344A1 Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
11/28/2012EP2527343A1 Heterocyclic compound having azole group
11/28/2012EP2527340A1 Piperazine compound having a pgds inhibitory effect
11/28/2012EP2527339A1 Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
11/28/2012EP2527338A1 N5-(2-ethoxyethyl)-n3-(2-pyridinyl) -3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
11/28/2012EP2527337A1 Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
11/28/2012EP2527336A1 Deuterated analogues of cilostazol
11/28/2012EP2527335A1 Triazole compounds as anti-inflammatory agents
11/28/2012EP2527332A1 4-Aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group as CDK9 inhibitors
11/28/2012EP2527330A1 Inhibitors of the hedgehog pathway
11/28/2012EP2527329A1 Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a serotonin receptor
11/28/2012EP2527328A1 Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
11/28/2012EP2527326A1 Novel compounds having 4-pyridylalkylthio group as substituent
11/28/2012EP2527323A1 Urea carbonyl disulfide derivatives and their therapeutic uses
11/28/2012EP2527322A1 Carbamyl alkylphenyl disulfide derivatives and their therapeutic uses
11/28/2012EP2527319A1 Crystalline forms of pregabalin and co-formers in the treatment of pain
11/28/2012EP2527315A1 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as Alzheimer's disease, type 2 diabetes and Parkinson's disease
11/28/2012EP2527008A2 Anticancerous polymeric agents
11/28/2012EP2527007A1 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
11/28/2012EP2527006A1 Quetiapine Formulation Having a Controlled-Release Coating
11/28/2012EP2526970A1 Monitoring cancer stem cells
11/28/2012EP2526969A1 Monitoring cancer stem cells
11/28/2012EP2526955A1 Lymphatic vessel stabilizer
11/28/2012EP2526953A1 Methods and pharmaceutical compositions for healing wounds
11/28/2012EP2526952A1 Methods and pharmaceutical compositions for healing wounds
11/28/2012EP2526951A1 Rhamno-polysaccharide from Enterococcus faecium clonal complex 17 and uses thereof
11/28/2012EP2526950A1 Solid oral dosage form containing an enhancer
11/28/2012EP2526949A1 Agents for treating migraine
11/28/2012EP2526948A1 RHO kinase inhibitors
11/28/2012EP2526947A1 Use of at least one isoquinoline compound of formula i, pharmaceutical composition for treating or preventing neurodegenerative diseases and method for treating or preventing neurodegenerative diseases
11/28/2012EP2526946A1 Methods Using 3-(4-Amino-1-Oxo-1,3-Dihydro-Isoindol-2-Yl)-Piperidine-2,6-Dione For Treatment Of Certain Leukemias
11/28/2012EP2526945A1 New CRTH2 Antagonists
11/28/2012EP2526944A1 Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
11/28/2012EP2526943A1 Liquid formulation comprising an alpha-2 receptor agonist (e.g. clonidin) and oxybutynin (anti-muscarinic agent) for the treatment of sialorrhoea
11/28/2012EP2526942A2 Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
11/28/2012EP2526941A1 Anti-inflammatory Modalities
11/28/2012EP2526940A2 Compositions containing enantiomeric equol, and methods for their making
11/28/2012EP2526939A1 Gelatine tannate and associations thereof for use in the treatment of inflammatory gastrointestinal diseases
11/28/2012EP2526938A2 Histidine decarboxylase inhibitor sole or combined with a leukotriene receptor antagonist, an anti-H1 and/or an anti-H2 to treat COPD or gastrointestinal disorders.
11/28/2012EP2526937A1 Composition for prevention of recurrence of stroke
11/28/2012EP2526936A1 Particle size distribution of cetyl myristate and/or cetyl palmitate
11/28/2012EP2526935A1 Hydrazidomycins
1 ... 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 ... 7860